A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis

COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We conducted a multicenter phase II study to evaluate the efficacy and safety of CP in patients with COVID-19, grade 4 or higher. To eval...

Full description

Bibliographic Details

Main Authors:	Vasiliki Pappa, Anthi Bouchla, Evangelos Terpos, Thomas P. Thomopoulos, Margherita Rosati, Dimitris Stellas, Anastasia Antoniadou, Andreas Mentis, Sotirios G. Papageorgiou, Marianna Politou, Anastasia Kotanidou, Ioannis Kalomenidis, Garyfalia Poulakou, Edison Jahaj, Eleni Korompoki, Sotiria Grigoropoulou, Xintao Hu, Jenifer Bear, Sevasti Karaliota, Robert Burns, Maria Pagoni, Ioannis Trontzas, Elisavet Grouzi, Stavroula Labropoulou, Kostantinos Stamoulis, Aristotelis Bamias, Sotirios Tsiodras, Barbara K. Felber, George N. Pavlakis, Meletios- Athanasios Dimopoulos
Format:	Artigo
Language:	Inglês
Published:	MDPI AG 2021-04-01
Series:	Microorganisms
Subjects:	convalescent plasma COVID-19 efficacy SARS-CoV-2 antibodies
Online Access:	https://www.mdpi.com/2076-2607/9/4/806
Tags:	Add Tag No Tags, Be the first to tag this record!